Limits...
A history of the term "DMARD".

Buer JK - Inflammopharmacology (2015)

Bottom Line: It then examines the usage of the terms "remission-inducing drugs" (RIDs) and "slow-acting anti-rheumatic drugs" (SAARDs), which for some years offered competition to the term DMARDs, thus underscoring the contingency of the establishment of DMARD as a word.Finally, it juxtaposes the apparently spontaneous emergence of the three terms DMARD, SAARD and RID, and the disappearance of the latter two, with a failed attempt in the early 1990s to replace these terms with the new term "disease-controlling antirheumatic treatment" (DC-ART).The analysis highlights the paradoxical qualities of the DMARD concept as robust albeit tension ridden, while playing down the role of identified individuals and overarching explanations of purpose.

View Article: PubMed Central - PubMed

Affiliation: Department of Social Anthropology, University of Oslo, Blindern, Postboks 1091, 0317, Oslo, Norway, j.k.buer@sai.uio.no.

ABSTRACT
The article outlines a history of the concept of "disease-modifying antirheumatic drugs" or DMARDs--from the emergence in the 1970s of the idea of drugs with decisive long-term effects on bone erosion in rheumatoid arthritis (RA), through the consolidation and popularisation in the term DMARD in 1980s and 1990s. It then examines the usage of the terms "remission-inducing drugs" (RIDs) and "slow-acting anti-rheumatic drugs" (SAARDs), which for some years offered competition to the term DMARDs, thus underscoring the contingency of the establishment of DMARD as a word. Finally, it juxtaposes the apparently spontaneous emergence of the three terms DMARD, SAARD and RID, and the disappearance of the latter two, with a failed attempt in the early 1990s to replace these terms with the new term "disease-controlling antirheumatic treatment" (DC-ART). The analysis highlights the paradoxical qualities of the DMARD concept as robust albeit tension ridden, while playing down the role of identified individuals and overarching explanations of purpose.

No MeSH data available.


Related in: MedlinePlus

Earliest use of the term “slow-acting anti-rheumatic drugs” identified in PubMed. With permission from Vischer (1979), Agents Actions Suppl, Springer Science+Business Media
© Copyright Policy - OpenAccess
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4508364&req=5

Fig4: Earliest use of the term “slow-acting anti-rheumatic drugs” identified in PubMed. With permission from Vischer (1979), Agents Actions Suppl, Springer Science+Business Media

Mentions: A second competing term was “slow-acting anti-rheumatic drugs” or SAARDs. PubMed searches revealed 47 publications that figured the phrase “slow-acting antirheumatic” or “slow-acting anti-rheumatic” in their title. The earliest article identified in the search was “To assess the effect of slow-acting anti-rheumatic drugs in man” (Vischer 1979, see Fig. 4), followed by “Slow-acting antirheumatic drugs” (Mowat 1982). The last publication identified was “New treatments for rheumatoid arthritis. Available and upcoming slow-acting antirheumatic drugs” (Fye 1999).6 After 1999, no authored publications in English registered in the PubMed database had the phrase “slow-acting antirheumatic drug” in its title.Fig. 4


A history of the term "DMARD".

Buer JK - Inflammopharmacology (2015)

Earliest use of the term “slow-acting anti-rheumatic drugs” identified in PubMed. With permission from Vischer (1979), Agents Actions Suppl, Springer Science+Business Media
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4508364&req=5

Fig4: Earliest use of the term “slow-acting anti-rheumatic drugs” identified in PubMed. With permission from Vischer (1979), Agents Actions Suppl, Springer Science+Business Media
Mentions: A second competing term was “slow-acting anti-rheumatic drugs” or SAARDs. PubMed searches revealed 47 publications that figured the phrase “slow-acting antirheumatic” or “slow-acting anti-rheumatic” in their title. The earliest article identified in the search was “To assess the effect of slow-acting anti-rheumatic drugs in man” (Vischer 1979, see Fig. 4), followed by “Slow-acting antirheumatic drugs” (Mowat 1982). The last publication identified was “New treatments for rheumatoid arthritis. Available and upcoming slow-acting antirheumatic drugs” (Fye 1999).6 After 1999, no authored publications in English registered in the PubMed database had the phrase “slow-acting antirheumatic drug” in its title.Fig. 4

Bottom Line: It then examines the usage of the terms "remission-inducing drugs" (RIDs) and "slow-acting anti-rheumatic drugs" (SAARDs), which for some years offered competition to the term DMARDs, thus underscoring the contingency of the establishment of DMARD as a word.Finally, it juxtaposes the apparently spontaneous emergence of the three terms DMARD, SAARD and RID, and the disappearance of the latter two, with a failed attempt in the early 1990s to replace these terms with the new term "disease-controlling antirheumatic treatment" (DC-ART).The analysis highlights the paradoxical qualities of the DMARD concept as robust albeit tension ridden, while playing down the role of identified individuals and overarching explanations of purpose.

View Article: PubMed Central - PubMed

Affiliation: Department of Social Anthropology, University of Oslo, Blindern, Postboks 1091, 0317, Oslo, Norway, j.k.buer@sai.uio.no.

ABSTRACT
The article outlines a history of the concept of "disease-modifying antirheumatic drugs" or DMARDs--from the emergence in the 1970s of the idea of drugs with decisive long-term effects on bone erosion in rheumatoid arthritis (RA), through the consolidation and popularisation in the term DMARD in 1980s and 1990s. It then examines the usage of the terms "remission-inducing drugs" (RIDs) and "slow-acting anti-rheumatic drugs" (SAARDs), which for some years offered competition to the term DMARDs, thus underscoring the contingency of the establishment of DMARD as a word. Finally, it juxtaposes the apparently spontaneous emergence of the three terms DMARD, SAARD and RID, and the disappearance of the latter two, with a failed attempt in the early 1990s to replace these terms with the new term "disease-controlling antirheumatic treatment" (DC-ART). The analysis highlights the paradoxical qualities of the DMARD concept as robust albeit tension ridden, while playing down the role of identified individuals and overarching explanations of purpose.

No MeSH data available.


Related in: MedlinePlus